Introduction
The predominant cause of Cushing's syndrome, after exclusion of exogenous glucocorticoid usage, is pituitary ACTH dependent form also defined as Cushing's disease (CD) general references (1) (2) (3) (4) which accounts for around 70-85% of cases (3) . Although rare, with an incidence reported to 2-3/million/yr -the variation partly or wholly depending on the stringency of diagnostic criteria. (3) . Some studies suggest CD is becoming more common due to greater awareness of its impact on vascular disease, diabetes mellitus, hypertension, opportunistic infections, and thromboembolic disease leading to more frequent screening. CD is most often insidious in onset and if undiagnosed and untreated leads to vastly increased morbidity and premature mortality. Further, population-based studies in older normal persons reported a significantly higher risk of death from cardiovascular disease for those with urinary free cortisol excretion (hazard ratio=5·0) 5 or salivary cortisol concentration (hazard ratio 1·6-1·8 6 in the highest versus those in the lowest tertile. Furthermore, in a large study of UK civil servants followed prospectively the hazard ratio for cardiovascular death was 1·9 for those with the slowest rate of fall in salivary cortisol throughout the day. 7 Moreover, increased all cause and cardiovascular mortality has been demonstrated in apparently non-Cushingoid subjects with adrenal incidentalomas whose cortisol levels fail to completely suppress with dexamethasone. 8, 9 The above evidence points to mild subclinical and chronic elevations in cortisol production being deleterious with respect to longevity. Several cohort studies 10-18 have examined whether mortality in CD is influenced by restoration of eucortisolism or not with variable results. The first metaanalysis of the early studies showed an overall standardised mortality ratio (SMR) of 2·2. 13 Pooled SMR (1·2) for patients in remission showed no significant increase in mortality which, however, was markedly increased for patients with persistent disease (SMR=5·5). Persistent disease, older age at diagnosis, treatment of hypertension and diabetes mellitus were the main determinants of increased mortality. Subsequent to that metaanalysis (13) there have been four further studies, from New Zealand (14) , Birmingham (15) , Oxford (17) and Bulgaria (18) , all confirming that patients in initial remission have better mortality outcome than those who do not achieve remission initially. When these were included in a recent metaanalysis (19) pooled SMR for patients in initial remission was 2·5 but there was considerable heterogeneity reflected by a wide range of SMR's (0·3 -10) . The individual studies contributing to the metaanalysis varied considerably in their definitions of remission and relapse and more importantly at what time after initial treatment remission was deemed to have occurred. In some instances remission was defined within a few weeks and in others up to 3 yrs dependent on the type of treatment (see refs. 13 & 19 for details). Moreover, a major limitation of all these individual studies was that the division of the cohorts was based on remission immediately after initial treatment with no information provided on relapse/recurrence of hypercortisolism during follow-up to census date, which could clearly drive mortality especialy from vascular disease. Therefore, in an attempt to remove these issues, minimise subject heterogeneity, and determine the very long-term survival for CD in remission the present multicentre study included only those patients who survived 10 yrs or more from the time of curative treatment and were in remission up until the census date or their death.
Materials and Methods
We performed a multicentre cohort study, the primary endpoint being mortality. The present study used an individual patient data approach combining data into a single database. Contributing centres were Birmingham UK; Oxford UK, Stoke-on-Trent UK; Leiden, Netherlands; Aalborg, Denmark; Auckland, New Zealand. Census dates at which the data were frozen were, 31/12/2013 (Birmingham), 31/12/2009 (Oxford), 1/12/2014 (Stoke-on-Trent), 1/1/2014 (Leiden), 1/1/2012 (Aalborg), 1/1/2012 (Auckland) or earlier, respectively. The patients included were all part of previous peer-reviewed publications (10, 11, 13, 14, 15, 17) Table 1 ). Follow-up for the present analyses started after 10 yrs of cure and no patients were lost to follow-up. The number or type of treatment to achieve cure was identified from the files with cure being defined after the last treatment. In the case of radiotherapy if this was given prophylactically to reduce the risk of Nelson's syndrome after bilateral adrenalectomy, the date of adrenalectomy was taken as cure date. The diagnostic criteria for CD and definition of remission could not be standardised and relied on those used by the individual centres which have all been published in their respective publications. 10,11,13,14,15,17 (and see supplementary Table 1 ) Similarly, treatment modalities varied between centres and with time. This was a retrospective study and initial diagnosis and treatment was from as early as 1958 (Stoke) through to 1997 (Leiden), see individual studies for details. In addition to demographic data and primary endpoint status of alive/dead and cause of death (from National Registry Offices or patient records) information was collected on initial treatment, subsequent treatments and dates thereof, radiotherapy usage, glucocorticoid and thyroxine replacement, and on treatment for hypertension and/or diabetes mellitus.
Statistical analysis
Continuous data are summarised as medians and ranges and discrete data as proportions. Survival data were graphically displayed using Kaplan-Meier plots and analysed using Cox regression. Factors associated with survival were examined individually with Cox regression analysis which included age at baseline as a covariate. Significance is taken as P<0·05 and confidence intervals, with no correction for multiple testing, are presented. Only age at study entry is included in the models, the other age variables given for information. There was no significant departure from proportional hazards assumptions for any of the variables. Standardised mortality ratios (SMRs) were calculated as the sum of the observed over the sum of the expected number of deaths in the entire cohort. Reference mortality rates were obtained via the Human Mortality Database for the relevant countries. Expected numbers of deaths used in the calculation of SMRs were calculated using standard cohort techniques described in detail in Breslow & Day (20) Denmark (1901 ), New Zealand (1948 -2008 , Netherlands (1901 Netherlands ( -2012 and UK (1922 UK ( -2013 . All analyses were carried out using Stata 13 (Stata v 13.1, Stata Corp, College Station, Texas).
Results

Baseline characteristics
There were 320 patients with 3790 person years of follow-up from 10 yrs after cure with a female:male ratio of 3:1. There were no significant differences between women and men with respect to any of the parameters shown in Table 1 , so data from the sexes were pooled for survival analysis and predictors thereof. The proportions with diabetes, hypertension, and on glucocorticoid replacement were similar in women and men. Treatment modalities are shown in Table 2 , with no difference between women and men. Over 80% of the cohort were initially treated with transsphenoidal pituitary surgery with 65% requiring only this modality to achieve long-term cure. However, 35% required additional treatment. Less than 10% had bilateral adrenalectomy or external radiotherapy as first treatment and these were those who entered the study in the early yrs (pre 1975) . Only 13% of the cohort required three or more treatments to achieve cure. The average parient follow-up was 11.8 years from study entry and was no different between countries. (see Table 4 ).
Mortality
In total 51 (16%) subjects died during follow-up from study entry (10 yrs post cure). The proportion was the same for women and men.(NS). Median (50%) survival for women was 31 yrs from study entry and 28 yrs for men (ns) (Fig 1A) . The median age at death was 69 yrs for women and 65 yrs for men and average time to death from 10 yrs post cure was 14 yrs. Among those patients who died there was no gender difference in age at cure; age at study entry, age at death; or duration of follow-up (Table 3) . However, when the sexes were combined and the deceased group compared with the alive group there were differences: age at cure (medians and ranges): alive=34 yrs vs dead = 14 (1-38) yrs P <0.005. The causes of death were predominantly circulatory (N=30) (included cardiovascular and cerebrovascular disease, ruptured aortic aneurysm, plus pulmonary embolism) in both women and men but all cancer deaths (N=9) occurred in women. There were only two recorded deaths from sepsis despite the fact that 68% of the cohort was on glucocorticoid replacement. The standardised mortality ratio (SMR) for all cause mortality was 1·61 (95% CI: 1·23-2·12) indicating a 61% increase in mortality risk (Table 4 ). In absolute terms this translates to five excess number of deaths per 1000 persons per yr beyond that what would be expected based on general population mortality rates. There was evidence for heterogeneity (P heterogeneity =0·03) between countries with Netherlands showing a low and New Zealand a high absolute observed risk ( 
Factors influencing mortality
Overall survival is depicted in the Kaplan-Meier plot in Fig 1A. Half the patients survived for 25 yrs or more from study entry (i.e. 35 yrs from cure). Factors associated with survival were examined with multivariate Cox regression analysis, including age at baseline as a covariate. Presence of diabetes had a hazard ratio of 2·82 (95% CI 1·29-6·17) (P<0·005), hypertension 1·59 (95% CI 0·77-3·31 NS There was an association between mortality and number of treatments, with higher risk with multimodal treatment (Fig 1B) . Hazard ratios were 1·77 (95% CI 0·93-3·38) for two vs one treatments (P=0·08), and 2·6 (1·15-5·87) for three vs one treatments (P=0·02). Median survival times from study entry were: one treatment=33 yrs (95% CI 26-38); two treatments=27 yrs (19- Table  3 ). Moreover patients cured by pituitary surgery only had a longer survival of 31 yrs vs 24 yrs if radiotherapy had been required at any time (P=0·03). Median survival for patients requiring bilateral adrenalectomy at any time was not reached 50% though for 75% survival it was 17 yrs vs 26 yrs for pituitary surgery only (P=0·1).
Discussion
The very long-term outcome of successfully treated CD is until now uncertain. Short-term studies 10-18 and metaanalyses have produced conflicting results 13,19 , not least because these studies were very heterogeneous with respect to the timing after initial treatment and how cure/remission was defined, and the duration of follow-up was relatively short. The first meta-analysis by Clayton et al. 13 suggested that SMR was not significantly increased, provided that patients achieved initial remission. But we were cautious in our conclusion stating 'patients in remission do not appear to have worse mortality but this should be regarded as preliminary'. Indeed, this caution was justified since two later studies one from New Zealand (14) , and one from Oxford (17) showed significantly increased SMRs for patients with CD in remission, although a large study from Bulgaria (18) did not. It is not clear why there is such a discrepancy between these later reports. The latest meta analysis with these three studies included (19) shows that the overall SMR for CD initially in remission was 2.5 (95% CI = 1. 4-4.2) and there was evidence of significant heterogeneity. In an attempt to clarify this issue patients in the present study were deliberately selected whose hypercortisolism had been cured for at least 10 yrs before study entry and remained cured for the duration of follow-up until census date or death. With this selected cohort of over 300 subjects and over three and a half thousand person years of follow-up since 10 years after cure we show that overall excess mortality is 60% (SMR = 1.6) higher than that of the general population from which they derive.
However, what we show here is that within cohorts of CD patients treated with different and several modalities over the years the mortality for patients treated with pituitary surgery alone have normal life expectancy. (SMR = 0.95). This is similar to the reports from purely surgical series from the USA with much shorter follow-up (Swearingen et al, Hammer et al). Overall 16% of the cohort died and the median age at death was >65 yrs, similar to that from earlier studies.The duration of follow-up for those who died was slightly longer(3yrs) than for those still alive, although there was no sex difference. The significance of this observation is uncertain. Interestingly, the SMR for men was not increased while it was for women. However, this SMR difference was not significant and should be interpreted with caution as there were only a quarter of deaths in men and the proportion of men that died was the same as for women. This indicates that more data are required for men.
There were no differences between women and men with respect to demographic data, treatment modalities or number of treatments, substitution therapy with glucocorticoid, or comorbidities of diabetes or hypertension, so the sexes were well-matched and so were combined for survival analysis and predictors of survival.
Compared to our published metaanalysis 13 and that of van Haalan et al. 19 the upper confidence limit for SMR in the present study was reduced from 3 to 4 to 2·3, and in absolute terms the excess mortality is small amounting to 5/1000 patient years of follow up. Moreover, duration of survival after cure in this highly selected cohort was long at about 40 yrs. (23, 24) , although in these studies patients with CD were excluded. In our study data were not available on growth hormone treatment, although for many GH was not available. Data were only available on gonadal hormone replacement in half the cohort so no meaningful conclusion can be drawn.. As in previous studies and summarised in our metaanalysis(13) treated diabetes conferred an independent risk for death, though hypertension did not. There is no obvious explanation for this difference given that half the cohort was receiving treatment for hypertension. The most interesting observation with regards to mortality risk was the clear trend to reduction in survival with increasing number of treatments required to achieve cure. Half those requiring only one treatment survived for 33 yrs from 10 yrs post cure while for those requiring three treatments the equivalent 50% survival was reduced by a third (21 yrs). This is perhaps not surprising as the number of treatments reflects the difficulty controlling hypercortisolaemia, and perhaps also the severity thereof. In 60% of patients the only treatment modality was pituitary surgery and these patients had the best outcome. The study limitations are: (1) Cohort study of (deliberately) highly selected patients who would be expected to be the healthiest and do well having already survived 10 yrs after cure before study entry which limits generalisability of the study, (2) Variable criteria for cure between centres which were highlighted in the metaanalyses. 13,19 , (3) We did not consider shorter remission duration of say 5 yrs before study entry which would include more patients and may have produced different outcomes. (4) Significant heterogeneity in SMRs from individual centres may limit the strength of the study, though this was eliminated when pituitary surgery was accounted for. (5) It was decided to exclude patients with a recurrence after 10 yrs of cure. From a methodological point of view this can be considered a form of selection bias (by selection on future events related to the outcome, but this selection was applied to assess the effect on mortality unrelated to Cushing recurrence. Importantly, the exclusion of patients with such a late recurrence is likely to have underestimated the increased mortality risk in the whole cohort.
Cause of death was predominantly circulatory which includes deaths from ischaemic heart disease, stroke, ruptured aortic aneurysms, and pulmonary emboli. There were too few deaths to analyse these seperately within this broad category or to compare meaningfully between the sexes. This confirms previous studies wherein cardiovascular disease was the main cause of the excess mortality. Cancer was not a contributor to excess mortality, which is in keeping with data from studies of patients with other forms of pituitary tumours wherein cancer deaths are not increased (reviewed in 25). As regards the cancer deaths in women these were from a variety of primary sources with none predominating.
Perhaps surprisingly given that two thirds of the cohort was receiving glucocorticoid replacement therapy there were only two deaths directly attributed to disseminated sepsis. When considering what drives the excess overall and circulatory mortality the total duration and degree of exposure to hypercortisolism may well be important. This is determined by several factors such as, but not exclusively, (1)time taken to reach a diagnosis which may be several years for a rare and insidious condition. There is no literature on this; (2) time taken from treatment to 'cure' which will depend on treatment number and modality; (3) posttreatment requirement for glucocorticoids replacement. In respect to the last point there is one published paper in acromegaly patients that higher dose of glucocorticoid treatment was an independent predictor of mortality (23). In our study data were not available on type, dose, frequency, or duration of glucocorticoid treatment. Were it available the variability thereof between centres and over an extended time period is unlikely to result in a large enough subgroup for meaningful analysis. And although we show an increase in SMR in patients treated with glucocorticoids this is not an independent risk factor in Cox regression analysis. Accordingly, at present we do not have a definitve answer to this important issue. Fewer patients who had pituitary surgery as only treatment were on steroids compared to other treament modalities. There is also evidence that hypogonadism and growth hormone deficiency are independent risk factors for mortality in hypopituitary patients
Advantages: (1) Large numbers of patients with prolonged follow-up of a rare disorder accurately defined and meticulously followed at referral centres experienced in dealing with this condition, (2) Rather than a meta-analysis of pooled patient data we obtained individual patient data from each participating centre, and (3) By obtaining results from geographically diverse regions these results are likely generalizable, at least to a Western European population.
What this study adds to the literature is a cohort of CD patients, treated by a variety of modalities, who have been 'permanently cured' with no recurrence, and no subjects lost to follow-up, for a very long time,
and still shows such subjects at increased risk for all cause and circulatory mortality. This is in a setting of 'best' clinical practice available at the time. However, within this overall cohort patients treated by pituitary surgery alone have normal long-term survival. We believe this to be a defining study on this topic, as a prospective study on this scale and for this duration is unlikely to be available for several years. What can we tell our patients with CD disease about their long-term survival prospects? From this study we can say that if you are cured for 10 yrs and remain without recurrence of hypercortisolism you will have a 60% increased risk of dying sooner than your peers, though in absolute terms this risk is small. Your survival after cure is 'on average' 40 yrs. However, should you be 'cured' by pituitary surgery alone your outcome appears to be excellent. You will, however, require life-long follow-up at an experienced centre having regular checks for diabetes, hypertension, and other cardiovascular risk factors. 2) 'normal' refers to the local reference range for the centre which varied by centre according to the assays used, and which themselves changed during the course of the follow-up 3) pl. = plasma; UFC = 24hr urine free cortisol; synacthen = synthetic ACTH 250 ug ; F-Up = follow up measured at variable regular intervals according to local protocols 4) o/n dex = plasma cortisol measured between 0800-1000 hrs following 1 or 2 mgs of dexamethasone administered at 2300 hrs the previous evening. The difference between numbers of treatments between centres was highly significant P <0.01
SUPPLEMENTARY
by Anova 
Supplementary
Supplementary Figure
Cumulative 
<1985 >=1985
The apparent difference was not significant.
